GeoVax Labs Inc.

GOVX Healthcare Biotechnology

GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 183.4%, EPS grew 88.9% and free cash flow grew 15.8%, each against the same quarter a year earlier.

0.23 0.03 −11.54%
Market cap
$2.6M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
n/a
Altman Z
−42.55
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.54 1.06 2.74 3.57
Net Debt/EBITDA
0.71 0.24 0.70 0.79
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.80) (1.76) (5.18) (7.66)
Book value per Share
0.39 0.25 3.99 6.05
Free Cash Flow
(3.66) (3.54) (4.96) (6.21)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates